Insight

IDH2 mutation accelerates TPO-induced myelofibrosis

Photo taken from Chien-Chin Lin/Researchgate

Aug 1, 2024, 03:00

IDH2 mutation accelerates TPO-induced myelofibrosis

Yu-Hung Wang, PhD student at The University of Manchester, shared a post on X about a recent paper by Chien-Chin Lin et al., commenting:

“IDH2 mutation accelerates thrombopoietin (TPO) induced myelofibrosis with enhanced S100a8/a9 and NFκB signaling in vivo.”

IDH2 mutation accelerates TPO-induced myelofibrosis with enhanced S100a8/a9 and NFκB signaling in vivo published in Wiley Online Library.

Authors: Chien-Chin Lin, Chi-Yuan Yao, Yu-Hung Wang, Yueh-Chwen Hsu, Chang-Tsu Yuan, Tsung-Chih Chen, Chia-Lang Hsu, Sze-Hwei Lee, Jhih-Yi Lee, Pin-Tsen Shih, Chein-Jun Kao, Po-Han Chuang, Yuan-Yeh Kuo, Hsin-An Hou, Wen-Chien Chou, Hwei-Fang Tien.

Yu-Hung Wang

Additional information
Source: Yu-Hung Wang/X

cancer Chang-Tsu Yuan Chein-Jun Kao Chi-Yuan Yao Chia-Lang Hsu Chien-Chin Lin Hsin-An Hou Hwei-Fang Tien IDH2 Jhih-Yi Lee myelofibrosis NFκB OncoDaily Oncology Pin-Tsen Shih Po-Han Chuang Sze-Hwei Lee Thrombopoietin Tsung-Chih Chen Wen-Chien Chou Yu-Hung Wang Yuan-Yeh Kuo Yueh-Chwen Hsu

Invest in Health Policy: A Conversation with Professor Andreas Charalambous

FDA Approves Cosibelimab-ipdl for Treatment of Metastatic or Locally Advanced Cutaneous Squamous Cell Carcinoma

Dolph Lundgren’s Fight for Life: How He Survived Kidney Cancer After 9 Years of Battle

Agenus and Tanner Pharma Partner to Expand Global Access to BOT/BAL

Bispecific Antibody M701 Offers a Novel Treatment Option for Malignant Ascites

Special Coverage